Skip to main content
SpringerLink
Log in

Hormonal Therapies in Cancers

  • Chapter
  • First Online:
Therapeutic Approaches in Cancer Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 185))

  • 690 Accesses

Abstract

The hormonal therapy for cancer has become a household name and the series of experiments performed leading to the discovery of hormones use in the treatments of breast cancer. The hormones like antiestrogen, aromatase restrictors, antiandrogens, and use of extremely strong luteinizing hormone-releasing hormone agonists to perform a “medical hypophysectomy” because of their ability of causing desensitization in the pituitary gland have proven their value in the treatment of cancers over the last two decades. Millions of women still use hormonal therapy for menopause symptoms. Estrogen plus progestin or estrogen separately utilized as a menopause hormonal therapy throughout the world. Women receiving different premenopausal and postmenopausal hormonal therapies are on higher risk of having ovarian cancer. The risk of ovarian cancer did not increase with the increase of duration of hormonal therapy. Postmenopausal hormone use was found to be inversely related to major colorectal adenomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI J Natl Cancer Inst 90(18):1371–1388

    Google Scholar 

  2. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548

    Article  CAS  PubMed  Google Scholar 

  3. Thomssen C, Jänicke F (2000) Do we need better prognostic factors in node-negative breast cancer? Pro. Eur J Cancer 36(3):293–298

    Article  CAS  PubMed  Google Scholar 

  4. MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharm Rev 50:151–196

    CAS  PubMed  Google Scholar 

  5. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Treleaven JG (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60(1):126–131

    Google Scholar 

  6. Assikis VJ, Jordan VC (1995) Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 49(3):241–257

    Article  CAS  Google Scholar 

  7. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91(19):1654–1662

    Google Scholar 

  8. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356(9233):881–887

    Article  CAS  PubMed  Google Scholar 

  9. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641–1647

    Google Scholar 

  10. Paterson R, Russell MH (1959) Clinical trials in malignant disease: Ppart II—breast cancer: value of irradiation of the ovaries. J Fac Radiol 10(3):130–133

    Article  CAS  PubMed  Google Scholar 

  11. Nissen-Meyer R (1991) Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 2(5):343–346

    Article  CAS  PubMed  Google Scholar 

  12. Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348(9036):1189–1196

    Article  Google Scholar 

  13. Stein JJ (1969) Surgical or irradiation castration for patients with advanced breast cancer. Cancer 24(6):1350–1354

    Article  CAS  PubMed  Google Scholar 

  14. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53(5):629–636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Blamey RW, Jonat W, Kaufmann M et al (1992) Goserelin depot in the treatment of pre-menopausal advanced breast cancer. Eur J Cancer 28A:810–814

    Article  CAS  PubMed  Google Scholar 

  16. Furr BJA (1989) Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res Paediatr 32(Suppl. 1):86–92

    Google Scholar 

  17. Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson JFR, Blamey RW (1990) Zoladex® plus tamoxifen versus zoladex® alone in pre-and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol 37(6):989–995

    Article  CAS  PubMed  Google Scholar 

  18. Trialists EBC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351:1451–1467

    Article  Google Scholar 

  19. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132):930–942

    Article  Google Scholar 

  20. Seidman H, Mushinski MH, Gelb S, Silverberg E (1985) Probabilities of eventually developing or dying of cancer—United States, 1985. CA Cancer J Clin 35(1):36–56

    Google Scholar 

  21. Daling JR, Malone KE, Voigt LF, White E, Weiss NS (1994) Risk of breast cancer among young women: relationship to induced abortion. JNCI J Natl Cancer Inst 86(21):1584–1592

    Google Scholar 

  22. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC (1996) Pregnancy termination in relation to risk of breast cancer. JAMA 275(4):283–287

    Article  CAS  PubMed  Google Scholar 

  23. Seidman H, Stellman SD, Mushinski MH (1982) A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin 32(5):301–313

    Google Scholar 

  24. Black LJ, Jones CD, Falcone JF (1983) Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32(9):1031–1036

    Article  CAS  PubMed  Google Scholar 

  25. Black LJ, Goode RL (1980) Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci 26(17):1453–1458

    Article  CAS  PubMed  Google Scholar 

  26. Jordan VC, Gosden B (1983) Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 113(2):463–468

    Google Scholar 

  27. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14(1):78–84

    Article  CAS  PubMed  Google Scholar 

  28. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. JNCI J Natl Cancer Inst 83(20):1488–1491

    Google Scholar 

  29. Rose PG (1996) Endometrial carcinoma. N Engl J Med 335(9):640–649

    Article  CAS  PubMed  Google Scholar 

  30. Wiklund I, Holst J, Karlberg J, Mattsson LÅ, Samsioe G, Sandin K, Von Schoultz B (1992) A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 14(3):211–224

    Google Scholar 

  31. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Cummings SR (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12)–1016–1037

    Google Scholar 

  32. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265(14):1861–1867

    Article  CAS  PubMed  Google Scholar 

  33. Lobo RA (1990) Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75(4 Suppl):18S-25S

    CAS  PubMed  Google Scholar 

  34. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA (1987) Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317(19):1169–1174

    Article  CAS  PubMed  Google Scholar 

  35. Miller BA, Feuer EJ, Hankey BF (1993) Recent incidence trends for breast cancer in women and the relevanceof early detection: an update. CA Cancer J Clin 43(1):27–41

    Google Scholar 

  36. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med 325(11):756–762

    Article  CAS  PubMed  Google Scholar 

  37. Rosen PP, Groshen S, Kinne D, Norton L (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11(11):2090–2100

    Article  CAS  Google Scholar 

  38. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339(8784):1–15

    Google Scholar 

  39. McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201–1207

    CAS  PubMed  Google Scholar 

  40. McMichael AJ, Potter JD (eds) (1985) Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 75(2):185–191

    Google Scholar 

  41. Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F, Franceschi S (1998) Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Prev Biomark 7(4):329–333

    CAS  Google Scholar 

  42. Furner SE, Davis FG, Nelson RL, Haenszel W (1989) A case-control study of large bowel cancer and hormone exposure in women. Can Res 49(17):4936–4940

    CAS  Google Scholar 

  43. Calle EE, Miracle-McMahill HL, Thun MJ, Heath Jr CW (1995) Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. JNCI J Natl Cancer Inst 87(7):517–523

    Google Scholar 

  44. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Stampfer MJ (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128(9):705–712

    Google Scholar 

  45. Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918

    Google Scholar 

  46. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø (2009) Hormone therapy and ovarian cancer. Jama 302(3):298–305

    Google Scholar 

  47. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE (2007) A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 121(10):2225–2232

    Article  CAS  PubMed  Google Scholar 

  48. Green J, Reeves GK, Floud S, Barnes I, Cairns BJ, Gathani T, Beral V (2019) Cohort profile: the million women study. Int J Epidemiol 48(1):28–29e

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Food Sciences, University of the Punjab, Quid-i-Azam Campus, Lahore, Pakistan

    Muhammad Rizwan Tariq, Shinawar Waseem Ali, Sehar Anam Khan, Roshan Yamen & Sara Iqbal

  2. Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan

    Waseem Safdar

  3. Department of Diet and Nutritional Sciences, Ibadat International University, Islamabad, Pakistan

    Muhammad Naveed Sheas

Authors
  1. Muhammad Rizwan Tariq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinawar Waseem Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sehar Anam Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roshan Yamen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sara Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Waseem Safdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Muhammad Naveed Sheas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Rizwan Tariq .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan

    Asma Saleem Qazi

  2. Respiratory Medicine, Castle Hill Hospital, Cottingham, UK

    Kanwal Tariq

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tariq, M.R. et al. (2023). Hormonal Therapies in Cancers. In: Qazi, A.S., Tariq, K. (eds) Therapeutic Approaches in Cancer Treatment. Cancer Treatment and Research, vol 185. Springer, Cham. https://doi.org/10.1007/978-3-031-27156-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-27156-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-27155-7

  • Online ISBN: 978-3-031-27156-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation